{"id":55160,"date":"2023-03-23T23:04:27","date_gmt":"2023-03-23T22:04:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/"},"modified":"2023-03-23T23:04:27","modified_gmt":"2023-03-23T22:04:27","slug":"graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/","title":{"rendered":"Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination"},"content":{"rendered":"
\n

THE WOODLANDS, Texas & SANTA ANA, Calif.–(BUSINESS WIRE)–Graf Acquisition Corp. IV (NYSE: GFOR) (\u201cGraf\u201d), a NYSE-listed special purpose acquisition company founded by serial SPAC founder James Graf, and NKGen Biotech, Inc. (\u201cNKGen Biotech\u201d), a biotechnology company focused on harnessing the power of the body\u2019s immune system through the development of natural killer cell therapies, announced today that they have signed a non-binding letter of intent (the \u201cLOI\u201d) to pursue a business combination.\n<\/p>\n

\nBased in Santa Ana, CA, NKGen Biotech was established in 2017 and is focused on natural killer cell therapies for the treatment of patients in areas such as neurodegenerative disease (e.g., Alzheimer\u2019s and Parkinson\u2019s) and oncology. NKGen Biotech is currently led by CEO Paul Y. Song, M.D., and Executive Chairman Sangwoo Park.\n<\/p>\n

\nGraf expects to announce additional details regarding the proposed business combination when a definitive merger agreement is executed.\n<\/p>\n

\nCompletion of a business combination between Graf and NKGen Biotech is subject to, among other things, the completion of due diligence, the negotiation of a definitive agreement providing for the transaction, the satisfaction of the conditions negotiated therein, and approval of the transaction by the board and shareholders of both Graf and NKGen Biotech. There can be no assurance that a definitive agreement will be entered into or that the proposed business combination will be consummated on the terms or timeframe currently contemplated, or at all.\n<\/p>\n

\nAbout NKGen Biotech, Inc.<\/b>\n<\/p>\n

\nNKGen Biotech, Inc. is a clinical-stage biotechnology company incorporated as a Delaware corporation and focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK Natural Killer (NK) cell therapeutics. The company is headquartered in Santa Ana, CA.\n<\/p>\n

\nAbout Graf Acquisition Corp. IV<\/b>\n<\/p>\n

\nGraf Acquisition Corp. (NYSE: GFOR) is a blank-check company incorporated as a Delaware corporation and formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.\n<\/p>\n

\nImportant Information and Where to Find It<\/b>\n<\/p>\n

\nIf a legally binding definitive agreement with respect to the proposed business combination is executed, Graf intends to file with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d) a registration statement, which will include a preliminary proxy statement\/prospectus (a \u201cProxy Statement\/Prospectus\u201d). A definitive Proxy Statement\/Prospectus will be mailed to Graf\u2019s stockholders as of a record date to be established for voting on the proposed business combination. Stockholders will also be able to obtain copies of the Proxy Statement\/Prospectus, without charge, at the SEC\u2019s website at www.sec.gov<\/a> or by directing a request to: Graf Acquisition Corp. IV, 1790 Hughes Landing Boulevard, Suite 400, The Woodlands, TX 77380.\n<\/p>\n

\nThis communication may be deemed to be offering or solicitation material in respect of the proposed business combination, which will be submitted to the stockholders of Graf for their consideration. Graf urges investors, stockholders and other interested persons to carefully read, when available, the preliminary and definitive Proxy Statement\/Prospectus as well as other documents filed with the SEC (including any amendments or supplements to the Proxy Statement\/Prospectus, as applicable), in each case, before making any investment or voting decision with respect to the proposed business combination, because these documents will contain important information about Graf, NKGen Biotech and the proposed business combination.\n<\/p>\n

\nParticipants in the Solicitation<\/b>\n<\/p>\n

\nGraf and NKGen Biotech and each of their directors and executive officers may be considered participants in the solicitation of proxies with respect to the proposed business combination described herein under the rules of the SEC. Information about the directors and executive officers of Graf and a description of their interests in Graf and the proposed business combination are set forth in Graf\u2019s Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 31, 2022 (the \u201cAnnual Report\u201d) and will be set forth in the Proxy Statement\/Prospectus, when it is filed with the SEC. Information about NKGen Biotech\u2019s directors and executive officers and a description of their interests in NKGen Biotech and the proposed business combination will be set forth in the Proxy Statement\/Prospectus, when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.\n<\/p>\n

\nNo Offer or Solicitation<\/b>\n<\/p>\n

\nThis release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of any business combination. This release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nCertain statements made in this release are \u201cforward looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this release, the words \u201cestimates,\u201d \u201cprojected,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cforecasts,\u201d \u201cplans,\u201d \u201cintends,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cfuture,\u201d \u201cpropose\u201d and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Graf\u2019s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include: the ability of Graf to enter into a definitive agreement with respect to a business combination with NKGen Biotech within the time provided in Graf\u2019s amended and restated certificate of incorporation; Graf\u2019s ability to obtain an extension of the business combination deadline provided for in Graf\u2019s amended and restated certificate of incorporation; Graf\u2019s ability to obtain the financing necessary to consummate the potential transaction; the performance of NKGen Biotech\u2019s business; the timing, success and cost of NKGen Biotech\u2019s product development activities and clinical trials; the risk that Graf\u2019s stockholder approval is not obtained; failure to realize the anticipated benefits of the proposed business combination, including as a result of a delay in consummating the proposed business combination; the amount of redemption requests made by Graf\u2019s stockholders and the amount of funds remaining in Graf\u2019s trust account after satisfaction of such requests; Graf\u2019s and NKGen Biotech\u2019s ability to satisfy the conditions to closing the proposed business combination; and those factors discussed in the Annual Report under the heading \u201cRisk Factors,\u201d and other documents of Graf filed, or to be filed, with the SEC. Graf does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nSabrina McKee
\n
EVP Strategy and Director, Graf Acquisition Corp. IV
\n
917-848-4902
\n
sabrina@grafacq.com<\/a>\n<\/p>\n

\nDenise Chua, MBA, CLS, MT (ASCP)
\n
Vice President, Investor Relations and Corporate Communications
\n
949-396-6830
\n
dchua@nkgenbiotech.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

THE WOODLANDS, Texas & SANTA ANA, Calif.–(BUSINESS WIRE)–Graf Acquisition Corp. IV (NYSE: GFOR) (\u201cGraf\u201d), a NYSE-listed special purpose acquisition company founded by serial SPAC founder James Graf, and NKGen Biotech, Inc. (\u201cNKGen Biotech\u201d), a biotechnology company focused on harnessing the power of the body\u2019s immune system through the development of natural killer cell therapies, announced … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55160","6":"format-standard","7":"category-industry"},"yoast_head":"\nGraf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"THE WOODLANDS, Texas & SANTA ANA, Calif.–(BUSINESS WIRE)–Graf Acquisition Corp. IV (NYSE: GFOR) (\u201cGraf\u201d), a NYSE-listed special purpose acquisition company founded by serial SPAC founder James Graf, and NKGen Biotech, Inc. (\u201cNKGen Biotech\u201d), a biotechnology company focused on harnessing the power of the body\u2019s immune system through the development of natural killer cell therapies, announced ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-23T22:04:27+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination\",\"datePublished\":\"2023-03-23T22:04:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\\\/\"},\"wordCount\":1226,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\\\/\",\"name\":\"Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2023-03-23T22:04:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/","og_locale":"en_US","og_type":"article","og_title":"Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination - Pharma Trend","og_description":"THE WOODLANDS, Texas & SANTA ANA, Calif.–(BUSINESS WIRE)–Graf Acquisition Corp. IV (NYSE: GFOR) (\u201cGraf\u201d), a NYSE-listed special purpose acquisition company founded by serial SPAC founder James Graf, and NKGen Biotech, Inc. (\u201cNKGen Biotech\u201d), a biotechnology company focused on harnessing the power of the body\u2019s immune system through the development of natural killer cell therapies, announced ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-23T22:04:27+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination","datePublished":"2023-03-23T22:04:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/"},"wordCount":1226,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/","url":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/","name":"Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2023-03-23T22:04:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/graf-acquisition-corp-iv-and-nkgen-biotech-inc-announce-letter-of-intent-for-a-business-combination\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55160"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55160\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}